|
1
|
Picci P: Osteosarcoma (osteogenic
sarcoma). Orphanet J Rare Dis. 2:62007. View Article : Google Scholar
|
|
2
|
Chou AJ, Geller DS and Gorlick R: Therapy
for osteosarcoma: where do we go from here? Paediatr Drugs.
10:315–327. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tan ML, Choong PF and Dass CR:
Osteosarcoma: Conventional treatment vs. gene therapy. Cancer Biol
Ther. 8:106–117. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Broadhead ML, Clark JC, Choong PF and Dass
CR: Making gene therapy for osteosarcoma a reality. Expert Rev
Anticancer Ther. 10:477–480. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Li XZ, Meng L, Chen AM, Guo FJ, Luo ZQ and
Zeng H: Screening of differentially expressed genes in osteosarcoma
cell lines with various metastatic potentialities. Zhonghua Zhong
Liu Za Zhi. 1:71–76. 2010.(In Chinese).
|
|
6
|
Li XZ, Meng L, Chen AM, Guo FJ, Luo ZQ and
Zeng H: Differentially expressed gene in osteosarcoma cell lines
with different metastatic potentials. J Nanjing Med Univ.
23:352–358. 2009. View Article : Google Scholar
|
|
7
|
Chen H, Huang Q, Dong J, Zhai DZ, Wang AD
and Lan Q: Overexpression of CDC2/CyclinB1 in gliomas, and CDC2
depletion inhibits proliferation of human glioma cells in vitro and
in vivo. BMC Cancer. 8:292008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Winkler K, Beron G, Kotz R, et al:
Neoadjuvant chemotherapy for osteogenic sarcoma: results of a
Cooperative German/Austrian study. J Clin Oncol. 2:617–624.
1984.PubMed/NCBI
|
|
9
|
Marina NM, Pratt CB, Rao BN, Shema SJ and
Meyer WH: Improved prognosis of children with osteosarcoma
metastatic to the lung(s) at the time of diagnosis. Cancer.
70:2722–2727. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kempf-Bielack B, Bielack SS, Jürgens H, et
al: Osteosarcoma relapse after combined modality therapy: an
analysis of unselected patients in the Cooperative Osteosarcoma
Study Group (COSS). J Clin Oncol. 23:559–568. 2005. View Article : Google Scholar
|
|
11
|
Oshima Y, Sasaki Y, Negishi H, et al:
Antitumor effect of adenovirus-mediated p53 family gene transfer on
osteosarcoma cell lines. Cancer Biol Ther. 6:1058–1066. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Walkley CR, Qudsi R, Sankaran VG, et al:
Conditional mouse osteosarcoma, dependent on p53 loss and
potentiated by loss of Rb, mimics the human disease. Genes.
22:1662–1676. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liang X, Da M, Zhuang Z, et al: Effects of
Survivin on cell proliferation and apoptosis in MG-63 cells in
vitro. Cell Biol Int. 33:119–124. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wu YF, Liang XJ, Liu YY, et al: +Antisense
oligonucleotide targeting survivin inhibits growth by inducing
apoptosis in human osteosarcoma cells MG-63. Neoplasma. 57:501–506.
2010.
|
|
15
|
Kim C, Shin E, Hong S, et al: Clinical
value of ezrin expression in primary osteosarcoma. Cancer Res
Treat. 41:138–144. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang YF, Shen JN, Xie XB, Wang J and Huang
G: Expression change of ezrin as a prognostic factor in primary
osteosarcoma. Med Oncol. 28(Suppl 1): S636–S643. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xu N and Chang DC: Different thresholds of
MPF inactivation are responsible for controlling different mitotic
events in mammalian cell division. Cell Cycle. 6:1639–1645. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kim DH: Prognostic implications of
cyclinB1, p34cdc2, p27(Kip1) and p53 expression in gastric cancer.
Yonsei Med J. 48:694–700. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chang JT, Wang HM, Chang KW, et al:
Identification of differentially expressed genes in oral squamous
cell carcinoma (OSCC): overexpression of NPM, CDK1 and NDRG1 and
underexpression of CHES1. Int J Cancer. 114:942–949. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Diril MK, Ratnacaram CK, Padmakumar VC, et
al: Cyclin-dependent kinase 1 (Cdk1) is essential for cell division
and suppression of DNA re-replication but not for liver
regeneration. Proc Natl Acad Sci USA. 109:3826–3831. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kim SJ, Nakayama S, Miyoshi Y, et al:
Determination of the specific activity of CDK1 and CDK2 as a novel
prognostic indicator for early breast cancer. Ann Onco. 19:68–72.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Choi HJ and Zhu BT: Critical role of
cyclin B1/Cdc2 up-regulation in the induction of mitotic
prometaphase arrest in human breast cancer cells treated with
2-methoxyestradiol. Biochim Biophys Acta. 1823:1306–1315. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhao MY, Auerbach A, D’Costa AM, et al:
Phospho-p70S6K/p85S6K and cdc2/cdk1 are novel targets for diffuse
large B-cell lymphoma combination therapy. Clin Cancer Res.
15:1708–1720. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Meyer A, Merkel S, Brückl W, et al: Cdc2
as prognostic marker in stage UICC II colon carcinomas. Eur J
Cancer. 45:1466–1473. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shi HR and Zhang RT: Expression and
significance of P53, P21WAF1 and CDK1 proteins in epithelial
ovarian cancer. Ai Zheng. 28:882–885. 2009.(In Chinese).
|
